Inventor · disambiguated record
Feng Zhou
Also filed as: ZHOU FENG
13 granted patents·14 pending applications·18 citations·filing 2009–2025
86Inventor score
Files withSHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD5FULCRUM THERAPEUTICS INC4RISEN SUZHOU PHARMA TECH CO LTD4SOLENT THERAPEUTICS LLC2TAKEDA PHARMACEUTICALS CO2
Top patents by PatentIndex Score
27 records- 0194US10973805B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2020·Granted Apr 13, 2021·5 cites·20 claims
- 0291US11590111B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2021·Granted Feb 28, 2023·2 cites·10 claims
- 0389US11225497B2Prodrugs of a CDK inhibitor for treating cancersRISEN SUZHOU PHARMA TECH CO LTD·Filed 2020·Granted Jan 18, 2022·2 cites·16 claims
- 0484US10464927B22,4-disubstituted pyrimidines as CDK inhibitorsSHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD·Filed 2018·Granted Nov 5, 2019·5 cites·7 claims
- 0583US2025195480A1Macrocyclic azolopyridine derivatives as eed and prc2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0682US11530234B2CD73 inhibitors and pharmaceutical uses thereofRISEN SUZHOU PHARMA TECH CO LTD·Filed 2020·Granted Dec 20, 2022·1 cites·21 claims
- 0781US12109198B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2022·Granted Oct 8, 2024·0 cites·5 claims
- 0876US10881681B2CD73 inhibitors and pharmaceutical uses thereofRISEN SUZHOU PHARMA TECH CO LTD·Filed 2019·Granted Jan 5, 2021·2 cites·21 claims
- 0975US11725020B2Prodrugs of a CDK inhibitor for treating cancersRISEN SUZHOU PHARMA TECH CO LTD·Filed 2021·Granted Aug 15, 2023·0 cites·20 claims
- 1069US9695175B2Highly selective c-Met inhibitors as anticancer agentsCROWN BIOSCIENCE INC (TAIWAN)·Filed 2013·Granted Jul 4, 2017·1 cites·35 claims
- 1163US2025340563A1Fused pyridazine derivatives as nlrp3 inhibitorsTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1261US2025188037A1N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivativesTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1359US2025122221A1Six-membered cyclothiazole compound and use thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1458US11814405B2Pyridine sulfonamide phosphate compound, preparation method therefor, and use thereofSHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD·Filed 2022·Granted Nov 14, 2023·0 cites·8 claims
- 1558US2024132473A1Sulfoximide substituted indazole irak4 kinase inhibitor, preparation method thereof and use thereofSHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD·Filed 2023·Application pending·0 cites
- 1656US2024391877A1Compound as inhibitor of complement factor d, and pharmaceutical composition and use thereofWUHAN CREATERNA SCIENCE AND TECH CO LTD·Filed 2022·Application pending·0 cites
- 1756US2024327425A1Kras g12d inhibitor and use thereofSHANGHAI DE NOVO PHARMATECH CO LTD·Filed 2022·Application pending·0 cites
- 1855US2025171414A1Compound serving as masp-2 inhibitor, pharmaceutical composition, preparation method therefor, and use thereofWUHAN CREATERNA SCIENCE AND TECH CO LTD·Filed 2023·Application pending·0 cites
- 1953US2024317755A1Heterocyclic compound, and intermediate thereof, preparation method therefor and use thereofWUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD·Filed 2022·Application pending·0 cites
- 2052US2025289792A13-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2SOLENT THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 2152US2023257382A1Heterocyclic compound and use thereofWUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD·Filed 2021·Application pending·0 cites
- 2251US2011178070A1PI3K/mTOR INHIBITORSTAKEDA PHARMACEUTICAL·Filed 2009·Application pending·0 cites
- 2350US12247015B23-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2SOLENT THERAPEUTICS LLC·Filed 2020·Granted Mar 11, 2025·0 cites·22 claims
- 2450US2022009951A1Torsemide phosphate prodrug, preparation method and composition thereofSHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD·Filed 2021·Application pending·0 cites
- 2548US12421238B2Selective dihydropyrrolopyrimidine JAK2 inhibitorsCHENGDU JINRUI FOUND BIOTECH CO LTD·Filed 2022·Granted Sep 23, 2025·0 cites·12 claims
- 2648US10351578B2Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereofSHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD·Filed 2018·Granted Jul 16, 2019·0 cites·5 claims
- 2738US2020277262A1N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivativesJONES BENJAMIN·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Feng Zhou files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →